...
首页> 外文期刊>Lung. >Cheyne-stokes respiration and prognosis in modern-treated congestive heart failure.
【24h】

Cheyne-stokes respiration and prognosis in modern-treated congestive heart failure.

机译:在现代治疗的充血性心力衰竭中,Cheyne刺激呼吸和预后。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In patients with congestive heart failure (CHF), a high prevalence of sleep-disordered breathing has been described. Cheyne-Stokes respiration (CSR) is present in up to 40% of patients with CHF. During the last decade, the medical treatment has been substantially improved. This study was designed to analyze the prognosis of CSR in modern-treated patients with CHF. For this purposes, in 57 patients with CHF who received modern treatment, a 5-year follow-up after initial full night polysomnography was performed. The mean follow-up period was 38 +/- 18 months. Mean age was 62 +/- 13 years and the mean ejection fraction was 25 +/- 7 percent. Respiratory polygraphy revealed CSR with a respiratory disturbance index >5 per hour of sleep in 39 of 57 patients. Twelve patients died. CSR was only characterized by a tendency of worsening (log-rank test, p = 0.25). However, there was a significant difference toward positive outcome for patients who received cardiac resynchronization therapy (log-rank test, p = 0.036). Using Multivariate Cox's proportional hazard regression with the factors resynchronization and CSR, the effect of resynchronization was almost significant (p = 0.08). In conclusion, no significant change of Cheyne-Stokes prevalence can be found in our small group of modern-treated patients with CHF. Cardiac resynchronization therapy was associated with improved patient outcome.
机译:在充血性心力衰竭(CHF)患者中,睡眠呼吸障碍的患病率很高。高达40%的CHF患者存在Cheyne-Stokes呼吸(CSR)。在过去的十年中,医学治疗得到了很大的改善。本研究旨在分析现代治疗的CHF患者中CSR的预后。为此,在接受现代治疗的57例CHF患者中,在最初的整夜多导睡眠图检查后进行了5年的随访。平均随访期为38 +/- 18个月。平均年龄为62 +/- 13岁,平均射血分数为25 +/- 7%。呼吸描记术显示57例患者中有39例CSR的睡眠呼吸干扰指数> 5每小时。十二名患者死亡。 CSR仅以恶化趋势为特征(对数秩检验,p = 0.25)。但是,接受心脏再同步治疗的患者在阳性结果方面存在显着差异(对数秩检验,p = 0.036)。使用多元Cox的比例风险回归与因素再同步和CSR,再同步的效果几乎是显着的(p = 0.08)。总之,在我们这一小组接受过现代治疗的CHF患者中,没有发现Cheyne-Stokes患病率的显着变化。心脏再同步治疗与改善患者预后相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号